Human relevance of NRAS/BRAF mouse melanoma models

European Journal of Cell Biology

Volumn 93, Issue 1-2, 2014, Pages 82-86

  Conde Perez, Alejandro ^a,b   Larue, Lionel ^a,b  

^a INSTITUT CURIE   (France)

^b Centre National de la Recherche Scientifique   (France)

Author keywords

Initiation; Melanomagenesis; Progression; PTEN; Catenin

Indexed keywords

B RAF KINASE; BETA CATENIN; MITOGEN ACTIVATED PROTEIN KINASE; N RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN P16; UNCLASSIFIED DRUG; WNT PROTEIN; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN;

CELL GROWTH; CELL PROLIFERATION; EXPERIMENTAL MOUSE; FOCAL ADHESION; GAIN OF FUNCTION MUTATION; GENETIC MANIPULATION; HETEROZYGOSITY LOSS; HUMAN; MELANOCYTE; MELANOMA; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; SENESCENCE; SHORT SURVEY; ANIMAL; CARCINOGENESIS; CELL AGING; EXPERIMENTAL MELANOMA; GENETICS; METABOLISM; MOUSE; PATHOLOGY; SKIN TUMOR;

ANIMALS; CARCINOGENESIS; CELL AGING; GTP PHOSPHOHYDROLASES; HUMANS; MELANOMA, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS;

EID: 84897496550     PISSN: 01719335     EISSN: 16181298     Source Type: Journal    
DOI: 10.1016/j.ejcb.2013.10.010     Document Type: Short Survey

References (48)

1. Ackermann J., Frutschi M., Kaloulis K., McKee T., Trumpp A., Beermann F. Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Research 2005, 65:4005-4011.
2. Balch C.M., Gershenwald J.E., Soong S.J., Thompson J.F., Atkins M.B., Byrd D.R., Buzaid A.C., Cochran A.J., Coit D.G., Ding S., Eggermont A.M., Flaherty K.T., Gimotty P.A., Kirkwood J.M., McMasters K.M., Mihm M.C., Morton D.L., Ross M.I., Sober A.J., Sondak V.K. Final version of 2009 AJCC melanoma staging and classification. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2009, 27:6199-6206.
3. Bardeesy N., Bastian B.C., Hezel A., Pinkel D., DePinho R.A., Chin L. Dual inactivation of RB and p53 pathways in RAS-induced melanomas. Molecular and Cellular Biology 2001, 21:2144-2153.
4. Bastian B.C., Olshen A.B., LeBoit P.E., Pinkel D. Classifying melanocytic tumors based on DNA copy number changes. American Journal of Pathology 2003, 163:1765-1770.
5. Bauer J., Curtin J.A., Pinkel D., Bastian B.C. Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. Journal of Investigative Dermatology 2007, 127:179-182.
6. Berlin I., Luciani F., Gallagher S.J., Rambow F., Conde-Perez A., Colombo S., Champeval D., Delmas V., Larue L. General strategy to analyse coat colour phenotypes in mice. Pigment Cell & Melanoma Research 2012, 25:117-119.
7. Bosenberg M., Muthusamy V., Curley D.P., Wang Z., Hobbs C., Nelson B., Nogueira C., Horner J.W., Depinho R., Chin L. Characterization of melanocyte-specific inducible Cre recombinase transgenic mice. Genesis 2006, 44:262-267.
8. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., Drake C.G., Camacho L.H., Kauh J., Odunsi K., Pitot H.C., Hamid O., Bhatia S., Martins R., Eaton K., Chen S., Salay T.M., Alaparthy S., Grosso J.F., Korman A.J., Parker S.M., Agrawal S., Goldberg S.M., Pardoll D.M., Gupta A., Wigginton J.M. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New England Journal of Medicine 2012, 366:2455-2465.
9. Chin L. Modeling malignant melanoma in mice: pathogenesis and maintenance. Oncogene 1999, 18:5304-5310.
10. Damsky W.E., Curley D.P., Santhanakrishnan M., Rosenbaum L.E., Platt J.T., Gould Rothberg B.E., Taketo M.M., Dankort D., Rimm D.L., McMahon M., Bosenberg M. beta-Catenin signaling controls metastasis in braf-activated pten-deficient melanomas. Cancer Cell 2011, 20:741-754.
11. Dankort D., Curley D.P., Cartlidge R.A., Nelson B., Karnezis A.N., Damsky W.E., You M.J., DePinho R.A., McMahon M., Bosenberg M. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nature Genetics 2009, 41:544-552.
12. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
13. Delmas V., Beermann F., Martinozzi S., Carreira S., Ackermann J., Kumasaka M., Denat L., Goodall J., Luciani F., Viros A., Demirkan N., Bastian B.C., Goding C.R., Larue L. Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes & Development 2007, 21:2923-2935.
14. Delmas V., Martinozzi S., Bourgeois Y., Holzenberger M., Larue L. Cre-mediated recombination in the skin melanocyte lineage. Genesis 2003, 36:73-80.
15. Demunter A., De Wolf-Peeters C., Degreef H., Stas M., van den Oord J.J. Expression of the endothelin-B receptor in pigment cell lesions of the skin. Evidence for its role as tumor progression marker in malignant melanoma. Virchows Archiv 2001, 438:485-491.
16. Dhomen N., Reis-Filho J.S., da Rocha Dias S., Hayward R., Savage K., Delmas V., Larue L., Pritchard C., Marais R. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 2009, 15:294-303.
17. Ferguson B., Konrad Muller H., Handoko H.Y., Khosrotehrani K., Beermann F., Hacker E., Soyer H.P., Bosenberg M., Walker G.J. Differential roles of the pRb and Arf/p53 pathways in murine naevus and melanoma genesis. Pigment Cell & Melanoma Research 2010, 23:771-780.
18. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., Chapman P.B. Inhibition of mutated, activated BRAF in metastatic melanoma. New England Journal of Medicine 2010, 363:809-819.
19. Gallagher S.J., Luciani F., Berlin I., Rambow F., Gros G., Champeval D., Delmas V., Larue L. General strategy to analyse melanoma in mice. Pigment Cell & Melanoma Research 2011, 24:987-988.
20. Garcia R.J., Ittah A., Mirabal S., Figueroa J., Lopez L., Glick A.B., Kos L. Endothelin 3 induces skin pigmentation in a keratin-driven inducible mouse model. Journal of Investigative Dermatology 2008, 128:131-142.
21. Gartner J.J., Parker S.C., Prickett T.D., Dutton-Regester K., Stitzel M.L., Lin J.C., Davis S., Simhadri V.L., Jha S., Katagiri N., Gotea V., Teer J.K., Wei X., Morken M.A., Bhanot U.K., Chen G., Elnitski L.L., Davies M.A., Gershenwald J.E., Carter H., Karchin R., Robinson W., Robinson S., Rosenberg S.A., Collins F.S., Parmigiani G., Komar A.A., Kimchi-Sarfaty C., Hayward N.K., Margulies E.H., Samuels Y. Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proceedings of the National Academy of Sciences of the United States of America 2013, 110:13481-13486.
22. Gembarska A., Luciani F., Fedele C., Russell E.A., Dewaele M., Villar S., Zwolinska A., Haupt S., de Lange J., Yip D., Goydos J., Haigh J.J., Haupt Y., Larue L., Jochemsen A., Shi H., Moriceau G., Lo R.S., Ghanem G., Shackleton M., Bernal F., Marine J.C. MDM4 is a key therapeutic target in cutaneous melanoma. Nature Medicine 2012, 18:1239-1247.
23. Goel V.K., Lazar A.J., Warneke C.L., Redston M.S., Haluska F.G. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. Journal of Investigative Dermatology 2006, 126:154-160.
24. Gomez L., Rubio M.P., Martin M.T., Vazquez J.J., Idoate M., Pastorfide G., Pestana A., Seizinger B.R., Barnhill R.L., Castresana J.S. Chromosome 17 allelic loss and NF1-GRD mutations do not play a significant role as molecular mechanisms leading to melanoma tumorigenesis. Journal of Investigative Dermatology 1996, 106:432-436.
25. Guldberg P., thor Straten P., Birck A., Ahrenkiel V., Kirkin A.F., Zeuthen J. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Research 1997, 57:3660-3663.
26. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.J., Kefford R., Wolchok J.D., Hersey P., Joseph R.W., Weber J.S., Dronca R., Gangadhar T.C., Patnaik A., Zarour H., Joshua A.M., Gergich K., Elassaiss-Schaap J., Algazi A., Mateus C., Boasberg P., Tumeh P.C., Chmielowski B., Ebbinghaus S.W., Li X.N., Kang S.P., Ribas A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. New England Journal of Medicine 2013, 369:134-144.
27. Hodi F.S., Corless C.L., Giobbie-Hurder A., Fletcher J.A., Zhu M., Marino-Enriquez A., Friedlander P., Gonzalez R., Weber J.S., Gajewski T.F., O'Day S.J., Kim K.B., Lawrence D., Flaherty K.T., Luke J.J., Collichio F.A., Ernstoff M.S., Heinrich M.C., Beadling C., Zukotynski K.A., Yap J.T., Van den Abbeele A.D., Demetri G.D., Fisher D.E. Imatinib for melanomas harboring mutationally activated or amplified kit arising on mucosal, acral, and chronically sun-damaged skin. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2013, 31:3182-3190.
28. Jang S., Atkins M.B. Which drug, and when, for patients with BRAF-mutant melanoma?. Lancet Oncology 2013, 14:e60-e69.
29. Kannan K., Sharpless N.E., Xu J., O'Hagan R.C., Bosenberg M., Chin L. Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:1221-1225.
30. Krauthammer M., Kong Y., Ha B.H., Evans P., Bacchiocchi A., McCusker J.P., Cheng E., Davis M.J., Goh G., Choi M., Ariyan S., Narayan D., Dutton-Regester K., Capatana A., Holman E.C., Bosenberg M., Sznol M., Kluger H.M., Brash D.E., Stern D.F., Materin M.A., Lo R.S., Mane S., Ma S., Kidd K.K., Hayward N.K., Lifton R.P., Schlessinger J., Boggon T.J., Halaban R. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nature Genetics 2012, 44:1006-1014.
31. Kunz M., Dannemann M., Kelso J. High-throughput sequencing of the melanoma genome. Experimental Dermatology 2013, 22:10-17.
32. Larue L., Beermann F. Cutaneous melanoma in genetically modified animals. Pigment Cell Research 2007, 20:485-497.
33. Luciani F., Champeval D., Herbette A., Denat L., Aylaj B., Martinozzi S., Ballotti R., Kemler R., Goding C.R., De Vuyst F., Larue L., Delmas V. Biological and mathematical modeling of melanocyte development. Development 2011, 138:3943-3954.
34. Maertens O., Johnson B., Hollstein P., Frederick D.T., Cooper Z.A., Messiaen L., Bronson R.T., McMahon M., Granter S., Flaherty K., Wargo J.A., Marais R., Cichowski K. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discovery 2013, 3:338-349.
35. Michaloglou C., Vredeveld L.C., Soengas M.S., Denoyelle C., Kuilman T., van der Horst C.M., Majoor D.M., Shay J.W., Mooi W.J., Peeper D.S. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005, 436:720-724.
36. Monahan K.B., Rozenberg G.I., Krishnamurthy J., Johnson S.M., Liu W., Bradford M.K., Horner J., Depinho R.A., Sharpless N.E. Somatic p16(INK4a) loss accelerates melanomagenesis. Oncogene 2010, 29:5809-5817.
37. Nikolaev S.I., Rimoldi D., Iseli C., Valsesia A., Robyr D., Gehrig C., Harshman K., Guipponi M., Bukach O., Zoete V., Michielin O., Muehlethaler K., Speiser D., Beckmann J.S., Xenarios I., Halazonetis T.D., Jongeneel C.V., Stevenson B.J., Antonarakis S.E. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nature Genetics 2012, 44:133-139.
38. Nogueira C., Kim K.H., Sung H., Paraiso K.H., Dannenberg J.H., Bosenberg M., Chin L., Kim M. Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene 2010, 29:6222-6232.
39. Rimm D.L., Caca K., Hu G., Harrison F.B., Fearon E.R. Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. American Journal of Pathology 1999, 154:325-329.
40. Siegel R., Naishadham D., Jemal A. Cancer statistics for Hispanics/Latinos, 2012. CA: A Cancer Journal for Clinicians 2012, 62:283-298.
41. Tsao H., Zhang X., Benoit E., Haluska F.G. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 1998, 16:3397-3402.
42. Vredeveld L.C., Possik P.A., Smit M.A., Meissl K., Michaloglou C., Horlings H.M., Ajouaou A., Kortman P.C., Dankort D., McMahon M., Mooi W.J., Peeper D.S. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes & Development 2012, 26:1055-1069.
43. Wadt K., Choi J., Chung J.Y., Kiilgaard J., Heegaard S., Drzewiecki K.T., Trent J.M., Hewitt S.M., Hayward N.K., Gerdes A.M., Brown K.M. A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma. Pigment Cell & Melanoma Research 2012, 25:815-818.
44. Whiteman D.C., Zhou X.P., Cummings M.C., Pavey S., Hayward N.K., Eng C. Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. International Journal of Cancer 2002, 99:63-67.
45. Wu H., Goel V., Haluska F.G. PTEN signaling pathways in melanoma. Oncogene 2003, 22:3113-3122.
46. Yajima I., Belloir E., Bourgeois Y., Kumasaka M., Delmas V., Larue L. Spatiotemporal gene control by the Cre-ERT2 system in melanocytes. Genesis 2006, 44:34-43.
47. You M.J., Castrillon D.H., Bastian B.C., O'Hagan R.C., Bosenberg M.W., Parsons R., Chin L., DePinho R.A. Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:1455-1460.
48. Zhou X.P., Gimm O., Hampel H., Niemann T., Walker M.J., Eng C. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. American Journal of Pathology 2000, 157:1123-1128.